Veronica Sanchez Bulis - 24 Dec 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: VP, Corporate Controller
Signature: /s/ Mark Meltz, Attorney-in-Fact
Issuer symbol: LYEL
Transactions as of: 24 Dec 2025
Net transactions value: -$74,181
Form type: 4
Filing time: 06 Jan 2026, 16:02:57 UTC
Previous filing: 12 Nov 2025
Next filing: 11 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bulis Veronica Sanchez	VP, Corporate Controller	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO	/s/ Mark Meltz, Attorney-in-Fact	06 Jan 2026	0002095702

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Sale	$43,929	-1,136	-12%	$38.67	8,077	24 Dec 2025	Direct	F1
transaction	LYEL	Common Stock	Sale	$30,252	-936	-12%	$32.32	7,141	30 Dec 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $38.6643 to $38.6751 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.